SunTrust analyst David MacDonald raised his price target on DaVita to $90 after its Q4 earnings beat yesterday, with the quarter also marked by "modestly better NATx growth, strong free cash flows, and an ongoing calcimimetics tailwind". The analyst adds that the company has an "attractive opportunity" with home care and Medicare Advantage business, and he believes that its ongoing investments to advance integrated care will further support its "strategic positioning". MacDonald further notes that DaVita's execution has been solid and its cash flow has been "robust".